![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Hands SoniVie Breakthrough Designation for PAH Treatment
FDA Hands SoniVie Breakthrough Designation for PAH Treatment
![](https://www.fdanews.com/ext/resources/test/Device_Images6/SoniVie_Logo.png?t=1568072498&width=430)
The FDA granted SoniVie breakthrough device designation for its Therapeutic Intravascular Ultrasound (TIVUS) system in patients with pulmonary arterial hypertension.
The system, a dedicated ultrasound catheter, is placed in the pulmonary artery during a heart catheterization procedure to ablate nerves associated with the disease’s effects.
The debilitating, life-threatening rare disease occurs when patients have high blood pressure in the vessels that move blood from the heart to the lungs.
Upcoming Events
-
21Oct